TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32248659
Drug: Ustekinumab (UST)
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab (UST) 90 mg subcutaneously at baseline and at weeks 4, 12, 20, 28, 36, and 44, combined with a 24-week prednisone taper.
Study: 32249038
Drug: PRIMA wireless
Normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRIMA wireless photovoltaic retinal implant
Study: 32249170
Drug: Non-Drug-Coated Balloon
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Drug-Coated Balloon (non-DCB)
Study: 32249171
Drug: Certification to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certification to prescribe and place subdermal contraceptive implants
Study: 32250517
Drug: Apatinib 500
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 500 mg single-agent
Study: 32251060
Drug: Subcutaneous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous tocilizumab (TCZ) 162 mg/wk in combination with csDMARDs for 24 weeks
Study: 32251060
Drug: Subcutaneous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous tocilizumab (TCZ) monotherapy continued until week 52 for patients who achieved remission at week 24
Study: 32251060
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with csDMARDs
Study: 32251621
Drug: Pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 10 mg/kg intravenously every 2 weeks (Cohort 1: PD-L1 expression at least 1%)
Study: 32251621
Drug: Pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 10 mg/kg intravenously every 2 weeks (Cohort 2: PD-L1 less than 1% or unevaluable)
Study: 32252538
Drug: Stanford Accelerated
Normalized name: Stangard
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) - 50 iTBS sessions, 1,800 pulses per session, delivered as 10 daily sessions over 5 consecutive days at 90% resting motor threshold.
Study: 32252720
Drug: Repetitive transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive transcranial magnetic stimulation (rTMS) treatment for CUD, duration: 90 days, targeted at the left dorsolateral prefrontal cortex.
Study: 32252720
Drug: Repetitive transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive transcranial magnetic stimulation (rTMS) treatment for CUD.
Study: 32252781
Drug: Adjuvant radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radiotherapy alone or in combination with chemotherapy
Study: 32252781
Drug: Adjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment (radiotherapy or chemotherapy)
Study: 32253717
Drug: Conivaptan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conivaptan (20 mg) administered every 12 hours for 2 days along with standard ICH management
Study: 32256049
Drug: Camrelizumab 1
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab 1 mg/kg, 3 mg/kg, 6 mg/kg, and 10 mg/kg every 2 weeks (dose-escalation phase)
Study: 32256049
Drug: Camrelizumab 200
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab 200 mg or 600 mg every 4 weeks (dose-expansion phase)
Study: 32256049
Drug: Camrelizumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab (all doses)
Study: 32256115
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acalabrutinib and obinutuzumab
Study: 32256270
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg caffeine plus 200 mg chlorogenic acid (CFCA)
Study: 32256270
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg caffeine plus 200 mg placebo (starch) (CFPL)
Study: 32256270
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg chlorogenic acid plus 200 mg placebo (CAPL)
Study: 32256270
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg placebo plus 200 mg placebo (PLPL)
Study: 32256610
Drug: Deciduous dental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deciduous dental pulp stem cells (DDPSC) associated with hydroxyapatite-collagen sponge (Bio-Oss Collagen® 250 mg, Geistlich)
Study: 32258591
Drug: Oculomotor and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oculomotor and gaze stability exercises applied at home twice a day for three weeks
Study: 32258956
Drug: Testosterone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (200 mg testosterone enanthate weekly)
Study: 32264715
Drug: iVAS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: iVAS therapy
Study: 32264726
Drug: FF-10501-01 (IMPDH
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF-10501-01 (IMPDH inhibitor)
Study: 32265627
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of autologous bone marrow mononuclear cells (BMMCs)
Study: 32266800
Drug: Progestin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestin treatment regimens (oral medroxyprogesterone acetate (MPA) 10 mg/day for 14 days per cycle, continuous MPA 10 mg/day, levonorgestrel-releasing intrauterine system (LNG-IUS))
Study: 32267227
Drug: Mandibular advancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular advancement device (MAD) treatment at a fixed 75% degree of maximal protrusion
Study: 34608859
Drug: Mandibular advancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular advancement device (MAD) treatment
Study: 32267967
Drug: EE4A chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE4A chemotherapy
Study: 32268821
Drug: Leflunomide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflunomide (20 mg and 40 mg)
Study: 32268821
Drug: Leflunomide (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflunomide (60 mg)
Study: 32268821
Drug: Leflunomide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflunomide (all doses)
Study: 32269146
Drug: Neoadjuvant PROSTVAC
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant PROSTVAC vaccine
Study: 32270053
Drug: simeprevir 150
Normalized name: simeprevir 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simeprevir 150 mg, daclatasvir 60 mg, sofosbuvir 400 mg once-daily for 12 weeks
Study: 32270056
Drug: Elbasvir/grazoprevir once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elbasvir/grazoprevir once-daily for 12 weeks
Study: 32270313
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 327 MBq (range 299-399 MBq) of folate receptor alpha-targeted agent
Study: 32271353
Drug: Durvalumab (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (1500 mg every 4 weeks) until disease progression or unacceptable toxic effects
Study: 32271899
Drug: Tisagenlecleucel infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tisagenlecleucel infusion with tocilizumab
Study: 32272183
Drug: Intensity modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity modulated radiation therapy (IMRT) with CTVp1 (60 Gy in 30 fractions)
Study: 32272183
Drug: Intensity modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity modulated radiation therapy (IMRT) with CTVp2 (54 Gy in 30 fractions)
Study: 32272183
Drug: Intensity modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity modulated radiation therapy (IMRT) with CTVp1 and CTVp2
Study: 32272514
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 50mg subcutaneous (SC) twice weekly for 12 weeks, followed by ETN 50mg SC once weekly for an additional 12 weeks.
Study: 32272921
Drug: Inhaled corticosteroid/long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid/long-acting β agonist (ICS/LABA)
Study: 32273476
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (BV) 1.8 mg/kg on day 1, and DHAP (dexamethasone 40mg days 1-4, cisplatin 100mg/m2; day 1, cytarabine 2x2g/m2; day 2)
Study: 32274381
Drug: YH4808 (potassium-competitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 (potassium-competitive acid blocker); specific dosage and duration not mentioned.
Study: 32274381
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and clarithromycin; specific dosages and duration not mentioned.
Study: 32274380
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) of gemigliptin/metformin sustained release 25/500 mg
Study: 32274380
Drug: Loose combination
Normalized name: loose wheat smut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loose combination of gemigliptin 50 mg and metformin extended release (XR) 500 mg
Study: 32274897
Drug: Overfeeding (additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overfeeding (additional 600 kcal, 30 g protein, 72 g carbohydrate, and 21 g fat) in CTs
Study: 32278280
Drug: DEB-TACE using
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEB-TACE using tightly calibrated 100-μm microspheres loaded with 50 mg of doxorubicin per millilitre
Study: 32278280
Drug: Doxorubicin dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin dose
Study: 32278621
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy (200-mg run-in dose followed by eight cycles of pembrolizumab with a taxane with or without carboplatin for 12 weeks, then doxorubicin and cyclophosphamide for an additional 12 weeks)
Study: 32279228
Drug: Bosutinib 400
Normalized name: bosutinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib 400 mg once daily (QD)
Study: 32279360
Drug: Chair resistance
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chair resistance training (RT) with sandbags/dumbbells, twice a week for 3 months
Study: 32279702
Drug: Therapeutic decisions
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic decisions (PAP vs conservative treatment)
Study: 32280268
Drug: Morphine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine group (M): received ultrasound-guided serratus anterior plane block with 20 mL of bupivacaine hydrochloride 0.25% plus 10 mg morphine sulfate
Study: 32280268
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C): received ultrasound-guided serratus anterior plane block with 20 mL of bupivacaine hydrochloride 0.25%
Study: 32280375
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of prebiotics and probiotics
Study: 32280529
Drug: Cataract surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cataract surgery in eyes with posterior capsule defect (PCD)
Study: 32280529
Drug: Cataract surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cataract surgery in eyes without posterior capsule abnormalities (PCA)
Study: 32282545
Drug: Laboratory preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laboratory preparation process
Study: 32283645
Drug: Probiotic multi-strain
Normalized name: Bacillus subtilis/Lactobacillus Sporogenes/Probiotic Cultures 1 BILLION CFU Oral Tablet, Chewable [DIGESTIVE ADVANTAGE PROBIOTIC MULTI-STRAIN ULTRA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic multi-strain formulation
Study: 32284384
Drug: Gepotidacin (GSK2140944),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepotidacin (GSK2140944), dosage and duration not specified
Study: 32285088
Drug: Mindful yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindful yoga intervention (1 hour, thrice weekly for 3 months)
Study: 32285998
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) at 15 mg/kg/day during radiation therapy and continued post-radiation, followed by bevacizumab at 10 mg/kg biweekly after radiation.
Study: 32285998
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) and bevacizumab after radiation therapy.
Study: 32286195
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT screening for lung cancer using Lung-RADS categories 3 or 4.
Study: 32287122
Drug: Machine-learning algorithm
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine-learning algorithm (SVM) using intranasal pressure sensor
Study: 32287128
Drug: Deep learning
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep learning model trained on sleep EEG data using dexmedetomidine as a prototype drug
Study: 32289161
Drug: Albuminuria (ACR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuminuria (ACR ≥30 mg/g) for ≥2 annual measurements classified as persistent albuminuria (PA).
Study: 32290838
Drug: Triptorelin SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin SR (11.25 mg) plus Tibolone (2.5 mg)
Study: 32293449
Drug: NT-proBNP >
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP > 88.64 pg/mL
Study: 32293449
Drug: NT-proBNP ≤
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP ≤ 88.64 pg/mL
Study: 32294561
Drug: IncobotulinumtoxinA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IncobotulinumtoxinA treatment for pes equinovarus
Study: 32295504
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose level ≤140 mg/dL
Study: 38160756
Drug: Pitavastatin calcium
Normalized name: PITAVASTATIN CALCIUM
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin calcium (4 mg/day) for 180 days
Study: 32296711
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation, dosage not specified, duration not specified
Study: 32296873
Drug: Ivosidenib 500-mg
Normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivosidenib 500-mg QD
Study: 32297945
Drug: Treatment Expectation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Expectation
Study: 32298288
Drug: Combined neoadjuvant
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined neoadjuvant chemotherapy with bevacizumab
Study: 32298699
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone treatment
Study: 32298699
Drug: Oral microbiota
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral microbiota
Study: 32298699
Drug: Sputum and
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sputum and oral microbiota
Study: 32298906
Drug: High RT
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High RT dose to the left hippocampus
Study: 32298906
Drug: RT dose
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RT dose to the left hippocampus, left temporal lobe, left frontal lobe, and total frontal lobe
Study: 32298906
Drug: RT dose
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RT dose to the thalamus and the left frontal lobe
Study: 32298906
Drug: RT dose
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RT dose to the brain and thalamus
Study: 32299118
Drug: Usual primary
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual primary care treatment in Dachau
Study: 32299817
Drug: CIVO microinjected
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIVO microinjected drugs
Study: 32300671
Drug: Intranasal Ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Ketamine
Study: 32300966
Drug: Propofol induction
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol induction dose
Study: 32300966
Drug: Higher propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher propofol doses
Study: 32300966
Drug: Excess propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Excess propofol dose
Study: 32301062
Drug: 0.2 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 ml/kg dose of IGIM
Study: 32301063
Drug: Dienogest 2
Normalized name: dienogest 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dienogest 2 mg/day
Study: 32301063
Drug: Other hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Other hormonal medications
Study: 32301063
Drug: Dienogest 2
Normalized name: dienogest 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dienogest 2 mg/day and other hormonal medications
Study: 32303379
Drug: QoR-15F scale
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QoR-15F scale administered pre-operation and on Postoperative day 1
Study: 32303514
Drug: Inappropriate reasons
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate reasons for ED presentation (no urgent treatment required)
Study: 32303994
Drug: Golimumab (GLM)
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab (GLM) as first-line biologic agent
Study: 32303994
Drug: Golimumab (GLM)
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab (GLM) as second-line biologic agent
Study: 32303994
Drug: Golimumab (GLM)
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab (GLM) as at least third-line biologic agent
Study: 32303994
Drug: Golimumab (GLM)
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab (GLM) in PsA as first-line biologic agent
Study: 32303994
Drug: Golimumab (GLM)
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab (GLM) in PsA as second-line biologic agent
Study: 32303994
Drug: Golimumab (GLM)
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab (GLM) in PsA as at least third-line biologic agent
Study: 32303994
Drug: Golimumab (GLM)
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab (GLM) in AS as first-line biologic agent
Study: 32303994
Drug: Golimumab (GLM)
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab (GLM) in AS as second-line biologic agent
Study: 32303994
Drug: Golimumab (GLM)
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab (GLM) in AS as at least third-line biologic agent
Study: 32304877
Drug: Biologics (n=557);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologics (n=557); 51% anti-immunoglobulin E, 48% anti-IL-5/IL-5Rα; 76% of initiations from May 2018 were anti-IL-5/IL-5Rα
Study: 32304877
Drug: Maintenance systemic
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance systemic corticosteroids (mSCS); median prednisone-equivalent daily dose of 10 mg
Study: 32304877
Drug: Patients of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients of hospital clinics, sites with fewer nonphysician staff, and with a recorded concurrent chronic obstructive pulmonary disease diagnosis
Study: 32306096
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept 2 mg/0.05 mL monthly for three injections followed by every 8 weeks
Study: 32307193
Drug: Substituting 50
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substituting 50 g/d egg for dairy products
Study: 32307193
Drug: Substituting 50
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substituting 50 g/d egg for nuts/legumes
Study: 32307193
Drug: Substituting 50
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substituting 50 g/d egg for red meat
Study: 32307279
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose inactivated hepatitis-A virus (HAV) vaccine
Study: 32307279
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose live attenuated varicella zoster virus (VZV) vaccine
Study: 32307279
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose VZV vaccine
Study: 32308505
Drug: FTD/TPI (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTD/TPI (35 mg/m²)
Study: 32309426
Drug: NAC+CHO (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAC+CHO (300 mL of oral carbohydrate administered 2 hours before surgery)
Study: 32309426
Drug: NAC (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAC (two cycles of chemotherapy followed by surgery)
Study: 32310146
Drug: AGE-ON tablet
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGE-ON tablet training program
Study: 32310699
Drug: Morphine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine treatment with metoclopramide coadministration